ecteinascidin 743 has been researched along with Fatigue in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfaro, V; Blay, JY; Chawla, SP; Hendifar, A; Hohenberger, P; Lardelli, P; Leahy, MG; Nguyen, BB; Nieto, A; Patel, SR; Penel, N; Piperno-Neumann, S; Santoro, A; Staddon, AP | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Gómez, J; Hidalgo, M; Jimeno, J; Lebedinsky, C; Mita, A; Mita, M; Rowinsky, EK; Schwartz, G; Zintl, P | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Lebedinsky, C; Mita, A; Nieto, A; Rowinsky, EK; Schwartz, G; Soto-Matos, A; Tolcher, AW | 1 |
| Colombo, N; del Campo, JM; Gómez, J; Gore, M; Kaye, S; Krasner, CN; McMeekin, S; Parekh, T; Park, YC; Sessa, C; Vermorken, JB; Zintl, P | 1 |
| Beijnen, JH; Bowman, A; Guzman, C; Hillebrand, MJ; Hoekman, K; Jimeno, J; López-Lázaro, L; Mathôt, RA; Rosing, H; Schellens, JH; Simpson, A; Smyth, J; Twelves, C; van Kesteren, C; Vermorken, JB | 1 |
1 review(s) available for ecteinascidin 743 and Fatigue
| Article | Year |
|---|---|
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Vomiting | 2013 |
4 trial(s) available for ecteinascidin 743 and Fatigue
| Article | Year |
|---|---|
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Creatine Kinase; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Transaminases; Young Adult | 2009 |
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2010 |
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Tetrahydroisoquinolines; Thrombocytopenia; Time Factors; Trabectedin; Urochordata | 2002 |